Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

127 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma.
Hultcrantz M, Hassoun H, Korde N, MacLachlan K, Mailankody S, Patel D, Shah UA, Tan CR, Chung DJ, Lahoud OB, Landau HJ, Scordo M, Shah GL, Giralt SA, Pianko MJ, Burge M, Barnett K, Salcedo M, Caple J, Tran L, Blaslov J, Shekarkhand T, Hamid S, Nemirovsky D, Derkach A, Arisa O, Peer CJ, Figg WD, Usmani SZ, Landgren O, Lesokhin AM. Hultcrantz M, et al. Among authors: lesokhin am. Blood Cancer J. 2024 Sep 19;14(1):164. doi: 10.1038/s41408-024-01136-1. Blood Cancer J. 2024. PMID: 39300066 Free PMC article. No abstract available.
Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease.
Landau H, Pandit-Taskar N, Hassoun H, Cohen A, Lesokhin A, Lendvai N, Drullinsky P, Schulman P, Jhanwar S, Hoover E, Bello C, Riedel E, Nimer SD, Comenzo RL. Landau H, et al. Leuk Lymphoma. 2012 Feb;53(2):275-81. doi: 10.3109/10428194.2011.606943. Epub 2011 Sep 23. Leuk Lymphoma. 2012. PMID: 21824051 Clinical Trial.
Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer Center.
Pozotrigo M, Adel N, Landau H, Lesokhin A, Lendvai N, Chung DJ, Chimento D, Riedel E, Chen X, Reich L, Comenzo R, Giralt S, Hassoun H. Pozotrigo M, et al. Bone Marrow Transplant. 2013 Aug;48(8):1033-9. doi: 10.1038/bmt.2012.281. Epub 2013 Jan 21. Bone Marrow Transplant. 2013. PMID: 23334269
Minimal residual disease in multiple myeloma: bringing the bench to the bedside.
Mailankody S, Korde N, Lesokhin AM, Lendvai N, Hassoun H, Stetler-Stevenson M, Landgren O. Mailankody S, et al. Among authors: lesokhin am. Nat Rev Clin Oncol. 2015 May;12(5):286-95. doi: 10.1038/nrclinonc.2014.239. Epub 2015 Jan 27. Nat Rev Clin Oncol. 2015. PMID: 25622976 Free PMC article. Review.
CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma.
Smith E, Devlin SM, Kosuri S, Orlando E, Landau H, Lesokhin AM, Chung DJ, Hassoun H, Lendvai N, Landgren O, Giralt S, Chari A, Jagannath S, Koehne G. Smith E, et al. Among authors: lesokhin am. Biol Blood Marrow Transplant. 2016 Feb;22(2):258-267. doi: 10.1016/j.bbmt.2015.08.025. Epub 2015 Aug 30. Biol Blood Marrow Transplant. 2016. PMID: 26325439 Free PMC article.
127 results